Trial Profile
A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs BI 144807 (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Feb 2020 This trial has been Discontinued in Germany according to European Clinical Trials Database record.
- 28 Feb 2020 Planned number of patients changed from 60 to 70.
- 11 May 2015 Status changed from suspended to completed as reported by ClinicalTrials.gov record.